Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Eli Lilly and Company (NYSE:LLY) stock is trading lower on Thursday after Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the advancement of its novel treatment for obesity, VK2735.
周四维京疗法公司（NASDAQ:VKTX）宣布其对肥胖症的新型治疗VK2735的进展，使Eli Lilly and Company（NYSE:LLY）股票交易走低。
The Details: Viking is advancing the injectable form of VK2735 to Phase 3 after receiving written feedback from an FDA Type C meeting. Also, the Phase 2 venture study of the drug yielded promising results.
详情：在接到FDA C类会议的书面反馈后，维京公司将VK2735注射剂推进到III期。此外，该药物的II期创业公司研究取得了有希望的结果。
VK2735 demonstrated an approximately 15% reduction in body weight from baseline following 13 weeks of treatment. The company anticipates scheduling an end-of-Phase 2 meeting with the FDA later this year.
在13周的治疗后，VK2735显示减轻基线体重约百分之15. 该公司预计今年晚些时候安排与FDA的II期结束会议（end-of-phase 2 meeting）的会议。
In addition, the Phase 1 study for the oral formulation of VK2735 demonstrated positive results. Participants reported a mean weight loss of up to 5.3% from baseline following 28 days of daily oral dosing. The company expects to start a Phase 2 study of this formulation during the fourth quarter of 2024.
此外，VK2735口服制剂的I期研究显示出积极成果。参与者报告称，他们在28天的每日口服剂量下与基线相比平均减重达到5.3％。该公司预计在2024年第四季度开始对该制剂进行II期研究。
Both forms of the new pharmaceutical appeared to be safe and well tolerated.
这两种新药物似乎都是安全和耐受性良好的。
Related Link: Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
相关链接：赛诺菲安万特（Sanofi）在强劲的第二季度收益和拳头产品Dupixent需求强劲的推动下，提高了2024年的利润预测。
LLY Price Action: As of Thursday morning, Eli Lilly shares are trading 4.19% lower at $823.87 per data from Benzinga Pro.
LLY价格行情：根据Benzinga Pro的数据，截至周四上午，Eli Lilly（丽 Lilly）股票以每股823.87美元的价格交易，下跌了4.19％。
Image: Photo by rafapress on Shutterstock
图片：来自Shutterstock的rafapress摄影